u/joe3000s

October 5, 2026

A recent study published in Nature Metabolism by researchers at Virginia Tech’s Fralin Biomedical Research Institute investigates whether industrial food processing itself influences human health independently of basic nutrient content. While ultra-processed foods (UPFs) are widely linked to obesity and diabetes, nutrition science has debated whether these poor health outcomes stem strictly from poor macronutrient profiles, such as high sugar and low fiber, or from the processing methods. To test this, researchers designed a randomized crossover trial using meals that were nutritionally matched within 1 percent for calories, carbohydrates, fats, proteins, water, and salt, utilizing the international NOVA food classification scale to compare highly processed meals against minimally processed ones.

​Participants consumed the matched meals inside a sealed metabolic chamber, allowing researchers to measure post-meal energy expenditure and blood metrics. The results revealed striking metabolic differences: the ultra-processed meals prompted a significantly higher insulin response, kept blood sugar elevated for longer, caused the body to expend more energy, and resulted in less carbohydrate burning for fuel. Furthermore, functional MRI (fMRI) brain scans showed that these metabolic shifts correlated directly with activity in the ventral striatum and nucleus accumbens - the brain regions responsible for motivation, learning, and reward.

​These findings offer novel neurobiological evidence that industrial processing alters how both the body and brain handle food in ways that go far beyond standard macronutrient labels, potentially helping to explain why ultra-processed foods are so easily overconsumed. The researchers aim to build on these insights by examining larger and more diverse populations, longer observation windows, and different food pairings to pinpoint the exact commercial additives or manufacturing steps driving these distinct physiological responses.

October 1, 2026

Coverage of the recent European Association for the Study of Diabetes (EASD) conference highlights how the next wave of metabolic and weight-loss therapies, specifically amylin-based medications, is set to transform the clinical landscape. While current GLP-1 receptor agonists have revolutionized obesity treatment, discontinuation rates remain fairly high, with roughly 40% of starting patients stopping their treatment within a year across all reasons. Amylin analogues act via distinct cellular receptors in the brain to curb appetite and slow gastric emptying, offering a complementary mechanism of action that achieves strong efficacy while causing severe nausea and vomiting at less than half the rate of GLP-1s.

​Clinical trial data for three leading amylin candidates is encouraging. Novo Nordisk reported that CagriSema, a weekly co-formulation combining semaglutide with the amylin analogue cagrilintide, produced a 22.4% mean weight loss after one year in overweight or obese patients. Brain fMRI studies further demonstrated that CagriSema reduced food fixations, while additional trial data indicated improvements in liver and pancreatic fat as well as diabetic neuropathic pain. Novo Nordisk has submitted CagriSema to the FDA for regulatory approval.

​Meanwhile, Eli Lilly presented results for EloraTZP, which combines its amylin analogue eloralintide with tirzepatide. In patients with obesity and Type 2 diabetes, EloraTZP delivered a 23% weight loss after nearly a year, compared to 14.8% for tirzepatide alone, alongside significant HbA1c reductions.

Additionally, Zealand Pharma shared phase trial data published in The Lancet for petrelintide, a standalone weekly amylin injection. Petrelintide achieved approximately 10% weight loss in non-diabetic participants while maintaining side-effect rates comparable to placebo, making it a promising candidate for standalone use.

​Ultimately, medical experts emphasise that the arrival of amylin-based therapies will allow clinicians to better individualise care based on patient tolerance and weight-loss goals. Because amylins provide a gentler side-effect profile, they may serve as an attractive first-line option for patients seeking moderate weight loss without severe GI disruption or as high-efficacy combination therapies for those requiring greater metabolic management.

Thanks to everyone who commented on yesterday’s poll! We got a solid sample size of 40 responses.

​Here is how the numbers broke down:

​A) Increased fatigue / lower energy: 24 votes (60.0%)

​B) No noticeable change / neutral: 15 votes (37.5%)

​C) Increased energy / reduced fatigue: 1 vote (2.5%)

​A majority (60%) experience notable fatigue or a drop in energy when using Cag, while just over a third (37.5%) don't notice any real impact. An increased energy response seems to be rare (only 2.5%).

October 2, 2026

Eli Lilly and Novo Nordisk are betting big on amylin therapies as the next frontier in obesity care because amylin acts on an entirely separate biological pathway from GLP-1, offering a distinct metabolic lever to suppress appetite and slow digestion. This dual-pathway approach allows drugmakers to build combination regimens, such as Lilly’s eloralintide with tirzepatide or Novo’s CagriSema, that can push weight loss further, break through GLP-1 plateaus, and directly reduce neurological food noise without relying solely on higher GLP-1 doses. Crucially, standalone amylin drugs also unlock a massive alternative treatment pool for patients who fail to respond to, tolerate, or achieve adequate weight loss on standard GLP-1 medications alone.

I've seen my fair share of posts across Reddit about Cag and fatigue. I was curious to see where everyone lands on this.

​Drop an A, B, or C in the comments below:

​A) Increased fatigue / lower energy

​B) No noticeable change / neutral

​C) Increased energy / reduced fatigue

I'm guessing for some voting A, this would have gone away after a few weeks or months.

Thanks for your time.

September 28, 2026

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

Presently, medications like semaglutide and tirzepatide are restricted to individuals with a BMI of 30 or higher, or a BMI of 27 with weight-related conditions. However, researchers analyzing data from over 313,000 individuals in the UK Biobank and the Copenhagen General Population Study found that roughly half of adults in the lower "overweight" BMI range of 25–26.9 suffer from elevated remnant cholesterol, chronic low-grade inflammation, or both.

​Crucially, the long-term data revealed that individuals in this lower BMI group who have elevated cholesterol or inflammation face the exact same elevated risk of developing coronary heart disease as those who currently qualify for GLP-1 prescriptions under existing guidelines. Because GLP-1 therapies are proven to reduce cardiovascular events, systemic inflammation, and harmful cholesterol levels, the study's lead researchers argue that prescribing criteria should be broadened to include this vulnerable population, though dedicated clinical trials will be needed to formalise the change.

​Eli Lilly and the FDA are locked in a quiet legal dispute over whether retatrutide should be classified as a biologic or a standard drug. The core of the disagreement centers on amino acid counts and whether the medication legally qualifies as a protein, which dictates whether Eli Lilly must file a standard New Drug Application (NDA) or a Biologics License Application (BLA).

​This classification battle carries massive financial stakes because a BLA grants a manufacturer 12 years of market exclusivity compared to just five years under an NDA. Even as the litigation remains unresolved, Eli Lilly is moving forward with plans to submit its regulatory package for approval.

​Beyond the obvious financial incentives and corporate profit margins driving this move, the push for BLA status is a strategic manoeuvre to attempt to crush the compounding market. By locking down a 12-year exclusivity window and securing tighter regulatory protections, they aim to choke off alternative supply chains and shut down peptide compounding.

​Even though pharma companies can use legal muscle to crush local compounding pharmacies, they don't have actual jurisdiction over overseas labs. So, while domestic crackdowns can wipe out local options, those regulatory attempts are unlikely to have much of an effect on the global grey market.

September 13, 2026

If you've ever posted about feeling cold or exhausted, you'll soon find others commenting and agreeing with you. Now, a new landmark study proves these collective experiences were spot on all along, and the literature is now catching up with this.

​A study from the University of Pennsylvania utilised AI processing to analyse over 400,000 Reddit posts on GLP-1/GIP medications. The researchers discovered that our real-world discussions picked up on physiological trends that formal clinical trials largely overlooked:

​Thermoregulatory Shifts (The Chills): Persistent coldness, sudden chills, and hot flashes appeared frequently across patient-reported data.

​Central Fatigue: Tiredness ranked as the second most common symptom in real-world dataset analysis, despite rarely reaching statistical reporting thresholds in early clinical drug trials.

​Endocrine & Menstrual Alterations: Nearly 4% of users detailing side effects logged cycle irregularities, spot-bleeding, or flow changes.

Rather than random anomalies, the researchers noted these symptoms correlate directly with the hypothalamus. Because GLP-1 and GIP receptor agonists target hypothalamic networks (the brain's command centre for not just appetite, but central body temperature, energy balance, and reproductive hormone regulation), these real-world effects make biological sense.

​​It’s a win for peer-led data and patient advocacy. While controlled trials are essential for safety, patient-led communities like this sub highlight how vital peer data is for uncovering the wider metabolic and hormonal shifts that don't always show up on a trial checklist.

September 12, 2026

​A new UC Berkeley study published in Nature evaluated whether semaglutide (Ozempic/Wegovy) affects the ageing process itself, testing the drug on 20-month-old mice (roughly equivalent to older adults).

​Key Takeaways:

​12% Lifespan Increase: Treated mice saw their median lifespan extended by nearly 100 days (12.4%), even though treatment wasn't started until late in life.

​Functional Upgrades: The semaglutide group showed measurable improvements in spatial memory, muscle function, blood sugar regulation, and reduced tissue inflammation.

​More Than Just Eating Less: To see if appetite suppression was the sole driver, researchers compared semaglutide directly against a 24% calorie-restricted diet. Semaglutide outperformed calorie restriction in cognitive behaviour, memory, and maintaining baseline metabolic rate (which dropped in the diet-only group).

​Novel Mechanism: The team concluded GLP-1 activation appears to tap into a distinct biological longevity pathway that goes beyond standard caloric reduction.

​Note: These results are currently limited to mouse models, and long-term clinical trials will be needed to see if these anti-aging effects translate to humans.

September 9, 2026

A recent analysis of over 113,000 private patients in England reveals a growing healthcare divide: private GLP-1 prescriptions for drugs like Mounjaro and Wegovy are lowest in the communities that need them most. While 3.4 million adults meet NICE criteria for these medications, the phased NHS rollout is projected to reach just 220,000 people over three years. This bottleneck leaves ability-to-pay as the primary gatekeeper for treatment, resulting in private prescription rates per person with obesity being 120% higher in affluent areas compared to deprived ones. Because lower-income populations face greater systemic drivers of obesity, like the high cost of nutritious food, this system effectively excludes those with the highest statistical need.

​This disparity is further compounded by the long-term nature of GLP-1 treatment, meaning maintenance often requires ongoing therapy. For private patients, this creates a continuous financial commitment that many struggle to afford over time. Ultimately, until public access through the NHS broadens significantly, relying on private prescribing will continue to widen UK health inequalities rather than bridge them.